| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Hui Min Chan, Ritesh Jain, Bo Ahrén, Giovanni Pacini, David Z D'Argeni. Effects of increasing doses of glucagon-like peptide-1 on insulin-releasing phases during intravenous glucose administration in mice. American journal of physiology. Regulatory, integrative and comparative physiology. vol 300. issue 5. 2011-06-30. PMID:21307364. |
in this study, a hierarchical population modeling approach is used, together with a previously reported model relating glucose to insulin appearance, to determine quantitative in vivo dose-response relationships between glp-1 dose level and both first- and second-phase insulin release. |
2011-06-30 |
2023-08-12 |
mouse |
| Hui Min Chan, Ritesh Jain, Bo Ahrén, Giovanni Pacini, David Z D'Argeni. Effects of increasing doses of glucagon-like peptide-1 on insulin-releasing phases during intravenous glucose administration in mice. American journal of physiology. Regulatory, integrative and comparative physiology. vol 300. issue 5. 2011-06-30. PMID:21307364. |
parameters of the insulin kinetic model were estimated from the complete set of glucose and insulin data collected in 219 anesthetized nonfasted nmr-imaged mice after intravenous injection of glucose (1 g/kg) alone or with glp-1 (0.03-100 nmol/kg). |
2011-06-30 |
2023-08-12 |
mouse |
| Hui Min Chan, Ritesh Jain, Bo Ahrén, Giovanni Pacini, David Z D'Argeni. Effects of increasing doses of glucagon-like peptide-1 on insulin-releasing phases during intravenous glucose administration in mice. American journal of physiology. Regulatory, integrative and comparative physiology. vol 300. issue 5. 2011-06-30. PMID:21307364. |
the resulting dose-response curves indicate a difference in glp-1 effect on the two release phases, as is also evident from the different ed(50) parameter values (0.107 vs. 6.65 nmol/kg for phase 1 vs. phase 2 insulin release parameters). |
2011-06-30 |
2023-08-12 |
mouse |
| Hui Min Chan, Ritesh Jain, Bo Ahrén, Giovanni Pacini, David Z D'Argeni. Effects of increasing doses of glucagon-like peptide-1 on insulin-releasing phases during intravenous glucose administration in mice. American journal of physiology. Regulatory, integrative and comparative physiology. vol 300. issue 5. 2011-06-30. PMID:21307364. |
the first phase of insulin release is gradually augmented with increasing glp-1 dose, reaching saturation at a dose of ~1 nmol/kg, while the second-phase release changes more abruptly at glp-1 doses between 3 and 10 nmol/kg and shows a more pronounced 100-fold increase between control and the high glp-1 dose of 100 nmol/kg moreover, separate disposition indices calculated for phase 1 and 2 insulin release, show a different pattern of increase with increasing glp-1 dose. |
2011-06-30 |
2023-08-12 |
mouse |
| S H Choi, H C Le. Long-term, antidiabetogenic effects of GLP-1 gene therapy using a double-stranded, adeno-associated viral vector. Gene therapy. vol 18. issue 2. 2011-06-28. PMID:20720576. |
our study results demonstrate that fasting blood glucose levels of db/db obese mice decreased significantly up to 4 months after a single injection of dsaav glp-1, and both insulin and circulating glp-1 levels increased in dsaav glp-1-infected mice. |
2011-06-28 |
2023-08-12 |
mouse |
| Madeleine Speck, Young Min Cho, Ali Asadi, Francesco Rubino, Timothy J Kieffe. Duodenal-jejunal bypass protects GK rats from {beta}-cell loss and aggravation of hyperglycemia and increases enteroendocrine cells coexpressing GIP and GLP-1. American journal of physiology. Endocrinology and metabolism. vol 300. issue 5. 2011-06-28. PMID:21304061. |
blood glucose levels and glucose tolerance were monitored, and the plasma insulin, glucagon-like peptide-1 (glp-1), and glucose-dependent insulinotropic polypeptide (gip) levels were measured. |
2011-06-28 |
2023-08-12 |
rat |
| Madeleine Speck, Young Min Cho, Ali Asadi, Francesco Rubino, Timothy J Kieffe. Duodenal-jejunal bypass protects GK rats from {beta}-cell loss and aggravation of hyperglycemia and increases enteroendocrine cells coexpressing GIP and GLP-1. American journal of physiology. Endocrinology and metabolism. vol 300. issue 5. 2011-06-28. PMID:21304061. |
compared with the sham-gk rats, the djb-gk rats had an increased β-cell area and a decreased islet fibrosis, increased insulin secretion with increased glp-1 secretion in response to a mixed meal, and an increased population of cells coexpressing gip and glp-1 in the jejunum anastomosed to the stomach. |
2011-06-28 |
2023-08-12 |
rat |
| Erik N Hansen, Robyn A Tamboli, James M Isbell, Jabbar Saliba, Julia P Dunn, Pamela A Marks-Shulman, Naji N Abumra. Role of the foregut in the early improvement in glucose tolerance and insulin sensitivity following Roux-en-Y gastric bypass surgery. American journal of physiology. Gastrointestinal and liver physiology. vol 300. issue 5. 2011-06-28. PMID:21372167. |
rygb resulted in an improved glucose, insulin, and glucagon-like peptide-1 (glp-1) area under the curve (auc) in the first 6 wk postoperatively (all p ≤ 0.018); there was no effect of delivery route (all p ≥ 0.632) or route × time interaction (all p ≥ 0.084). |
2011-06-28 |
2023-08-12 |
human |
| Erik N Hansen, Robyn A Tamboli, James M Isbell, Jabbar Saliba, Julia P Dunn, Pamela A Marks-Shulman, Naji N Abumra. Role of the foregut in the early improvement in glucose tolerance and insulin sensitivity following Roux-en-Y gastric bypass surgery. American journal of physiology. Gastrointestinal and liver physiology. vol 300. issue 5. 2011-06-28. PMID:21372167. |
the ratio of insulin auc to glp-1 and gip auc decreased after surgery (p =.001 and 0.061, respectively) without an effect of delivery route over time (both p ≥ 0.646). |
2011-06-28 |
2023-08-12 |
human |
| Paula L McClean, Vadivel Parthsarathy, Emilie Faivre, Christian Hölsche. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 31. issue 17. 2011-06-24. PMID:21525299. |
the incretin hormone glucagon-like peptide-1 (glp-1) facilitates insulin signaling, and novel long-lasting glp-1 analogs, such as liraglutide, are on the market as diabetes therapeutics. |
2011-06-24 |
2023-08-12 |
mouse |
| J Philip Karl, Andrew J Young, Scott J Montai. Eating rate during a fixed-portion meal does not affect postprandial appetite and gut peptides or energy intake during a subsequent meal. Physiology & behavior. vol 102. issue 5. 2011-06-21. PMID:21238470. |
fullness, measured by the satiety labeled intensity magnitude (slim) scale, serum insulin, glucose, leptin, pancreatic polypeptide (pp), pyy, glp-1, neuropeptide-y, and plasma cholecystokinin (cck) were measured for 3h following the fixed-portion meal. |
2011-06-21 |
2023-08-12 |
human |
| Chuan-an Shen, Shawn Fagan, Alan J Fischman, Edward E Carter, Jia-Ke Chai, Xiao-Ming Lu, Yong-Ming Yu, Ronald G Tompkin. Effects of glucagon-like peptide 1 on glycemia control and its metabolic consequence after severe thermal injury--studies in an animal model. Surgery. vol 149. issue 5. 2011-06-21. PMID:21295809. |
the most potent insulinotropic hormone, glucagon-like peptide 1 (glp-1), stimulates insulin secretion in a glucose-dependent manner. |
2011-06-21 |
2023-08-12 |
Not clear |
| Chuan-an Shen, Shawn Fagan, Alan J Fischman, Edward E Carter, Jia-Ke Chai, Xiao-Ming Lu, Yong-Ming Yu, Ronald G Tompkin. Effects of glucagon-like peptide 1 on glycemia control and its metabolic consequence after severe thermal injury--studies in an animal model. Surgery. vol 149. issue 5. 2011-06-21. PMID:21295809. |
because infusion of glp-1 never reduces glucose levels to below ∼70 mg/dl, the risk of hypoglycemia by using insulin is reduced. |
2011-06-21 |
2023-08-12 |
Not clear |
| P Anagnostis, V G Athyros, F Adamidou, A Panagiotou, M Kita, A Karagiannis, D P Mikhailidi. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes, obesity & metabolism. vol 13. issue 4. 2011-06-17. PMID:21205117. |
glp-1 exerts its glucose-regulatory action via stimulation of insulin secretion and glucagon suppression by a glucose-dependent way, as well as by weight loss via inhibition of gastric emptying and reduction of appetite and food intake. |
2011-06-17 |
2023-08-12 |
human |
| Alessia Santoprete, Elena Capitò, Paul E Carrington, Alessandro Pocai, Marco Finotto, Annunziata Langella, Paolo Ingallinella, Karolina Zytko, Simone Bufali, Simona Cianetti, Maria Veneziano, Fabio Bonelli, Lan Zhu, Edith Monteagudo, Donald J Marsh, Ranabir Sinharoy, Elisabetta Bianchi, Antonello Pess. DPP-IV-resistant, long-acting oxyntomodulin derivatives. Journal of peptide science : an official publication of the European Peptide Society. vol 17. issue 4. 2011-06-17. PMID:21294225. |
therapies based on peptide mimetics of the gut hormone glucagon-like peptide 1 (glp-1) are rapidly gaining favor, due to their ability to increase insulin secretion in a strictly glucose-dependent manner, with little or no risk of hypoglycemia, and to their additional benefit of causing a modest, but durable weight loss. |
2011-06-17 |
2023-08-12 |
mouse |
| J F Rehfel. Incretin physiology beyond glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: cholecystokinin and gastrin peptides. Acta physiologica (Oxford, England). vol 201. issue 4. 2011-06-17. PMID:21392266. |
under these unphysiological conditions, the release of gastrin and cck and, hence, their effect on insulin secretion are modest in comparison with the effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 (glp-1). |
2011-06-17 |
2023-08-12 |
mouse |
| Piotr Borkiewicz, Maciej Pawlak, Paweł Mackowia. The results of prolonged action of GLP-1 on some metabolic parameters. Folia biologica. vol 59. issue 1-2. 2011-06-16. PMID:21614961. |
moreover, glp-1 decreases the level of glucose in the blood, independently of insulin. |
2011-06-16 |
2023-08-12 |
rat |
| Woo-Jin Song, Madhav Seshadri, Uzair Ashraf, Thembi Mdluli, Prosenjit Mondal, Meg Keil, Monalisa Azevedo, Lawrence S Kirschner, Constantine A Stratakis, Mehboob A Hussai. Snapin mediates incretin action and augments glucose-dependent insulin secretion. Cell metabolism. vol 13. issue 3. 2011-06-15. PMID:21356520. |
treatment with the incretin hormone glucagon-like peptide-1 (glp-1) potentiates insulin secretion and improves metabolic control in humans with t2dm. |
2011-06-15 |
2023-08-12 |
Not clear |
| Woo-Jin Song, Madhav Seshadri, Uzair Ashraf, Thembi Mdluli, Prosenjit Mondal, Meg Keil, Monalisa Azevedo, Lawrence S Kirschner, Constantine A Stratakis, Mehboob A Hussai. Snapin mediates incretin action and augments glucose-dependent insulin secretion. Cell metabolism. vol 13. issue 3. 2011-06-15. PMID:21356520. |
glp-1 receptor-mediated signaling leading to insulin secretion occurs via cyclic amp stimulated protein kinase a (pka)- as well as guanine nucleotide exchange factor-mediated pathways. |
2011-06-15 |
2023-08-12 |
Not clear |
| Craig W Spellma. Pharmacology of GLP-1 agonists: describing the therapeutic potential to patients. The Journal of the American Osteopathic Association. vol 111. issue 2 Suppl 1. 2011-06-09. PMID:21389294. |
glucagon-like peptide-1 (glp-1) agonists, which improve insulin secretion, decrease glucagon secretion, increase satiety (and therefore decrease food intake), and may have beneficial effects on β-cell function, represent an important addition to treatment options. |
2011-06-09 |
2023-08-12 |
Not clear |